+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • January 2024
  • Region: Global
  • Grand View Research
  • ID: 5513871
Description Jump to:
The global advanced therapy medicinal products CDMO market is expected to reach USD 18.8 billion by 2030. The market is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.

With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.

Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.

On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac’s mRNA-based COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.

Advanced Therapy Medicinal Products CDMO Market Report Highlights

  • The gene therapy segment held the largest share of over 49.2% in 2023. Increase in financial support and rise in number of clinical trials for gene therapies are driving demand for the gene therapy segment.
  • The cell therapy segment is expected to show lucrative growth over the forecast period. The field of cellular therapeutics is constantly advancing with inclusion of new cell types, which, in turn, provides ample opportunities for companies to enhance their market positions.
  • The oncology segment accounted for the largest revenue share in 2023. The segment’s dominance is attributed to disease burden, strategic initiatives undertaken by key players, and availability of advanced therapies used for treating various cancer indications.
  • The phase I segment dominated the market in 2023 due to growing R&D activities and increasing number of human trials for advanced therapies.
  • North America dominated the overall market share of 49% in 2023. This can be attributed to increasing outsourcing activities and rising awareness about advanced therapy.
  • The Asia-Pacific region is expected to grow at the fastest CAGR over the forecast period due to the increasing demand for novel ATMPs and rising R&D activities to develop novel therapies.

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation And Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Phase Segment
1.1.1.3. Indication Segment
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List Of Primary Sources
1.11. List Of Abbreviations
Chapter 2. Advanced Therapy Medicinal Products CDMO Market: Executive Summary
2.1. Market Snapshot
2.2. Products Snapshots
2.3. Phase Snapshots
2.4. Indication Snapshot
2.5. Competitive Landscape Snapshot
Chapter 3. Advanced Therapy Medicinal Products CDMO Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising number of clinical trials for ATMPs
3.4.2. Increasing outsourcing activities
3.4.3. Growing awareness of the treatment
3.5. Market Restraint Analysis
3.5.1. Stringent regulatory approvals
3.5.2. High cost of outsourcing
3.6. Advanced Therapy Medicinal Products CDMO Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat Of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
Chapter 4. Advanced Therapy Medicinal Products CDMO: Products Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Advanced Therapy Medicinal Products CDMO Market, by Product Outlook
4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
4.4.1. Gene Therapy
4.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
4.4.2. Cell Therapy
4.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
4.4.3. Tissue Engineered
4.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
4.4.4. Others
4.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 5. Advanced Therapy Medicinal Products CDMO: Phase Estimates & Trend Analysis
5.1. Phase Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Advanced Therapy Medicinal Products CDMO Market, by Phase Outlook
5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
5.4.1. Phase I
5.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
5.4.2. Phase II
5.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
5.4.3. Phase III
5.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
5.4.4. Phase IV
5.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 6. Advanced Therapy Medicinal Products CDMO: Indication Estimates & Trend Analysis
6.1. Indication Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Advanced Therapy Medicinal Products CDMO Market, by Indication Outlook
6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
6.4.1. Oncology
6.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.2. Cardiology
6.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.3. Central Nervous System
6.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.4. Musculoskeletal
6.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.5. Infectious Disease
6.4.5.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.6. Dermatology
6.4.6.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.7. Endocrine, Metabolic, Genetic
6.4.7.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.8. Immunology & Inflammation
6.4.8.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.9. Ophthalmology
6.4.9.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.10. Hematology
6.4.10.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.11. Gastroenterology
6.4.11.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.12. Others
6.4.12.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. U.S. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Canada Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. UK Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Germany Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.3. Spain
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Spain Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.4. France
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. France Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.5. Italy
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Italy Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.6. Denmark
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Denmark Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Sweden Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.8. Norway
7.6.8.1. Key Country Dynamics
7.6.8.2. Competitive Scenario
7.6.8.3. Regulatory Framework
7.6.8.4. Norway Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7. Asia-Pacific
7.7.1. Japan
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Japan Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.2. China
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. China Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.3. India
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. India Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.4. South Korea
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Framework
7.7.4.4. South Korea Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.5. Thailand
7.7.5.1. Key Country Dynamics
7.7.5.2. Competitive Scenario
7.7.5.3. Regulatory Framework
7.7.5.4. Thailand Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.6. Australia
7.7.6.1. Key Country Dynamics
7.7.6.2. Competitive Scenario
7.7.6.3. Regulatory Framework
7.7.6.4. Australia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. Brazil Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Mexico Advanced Therapy Medicinal Products CDMO Market, 2018-2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Argentina Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9. MEA
7.9.1. MEA Advanced Therapy Medicinal Products CDMO Market, 2018-2030 (USD Million)
7.9.2. South Africa
7.9.2.1. Key Country Dynamics
7.9.2.2. Competitive Scenario
7.9.2.3. Regulatory Framework
7.9.2.4. South Africa Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key Country Dynamics
7.9.3.2. Competitive Scenario
7.9.3.3. Regulatory Framework
7.9.3.4. Saudi Arabia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9.4. UAE
7.9.4.1. Key Country Dynamics
7.9.4.2. Competitive Scenario
7.9.4.3. Regulatory Framework
7.9.4.4. UAE Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key Country Dynamics
7.9.5.2. Competitive Scenario
7.9.5.3. Regulatory Framework
7.9.5.4. Kuwait Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company /Competition Categorization
8.3. Vendor Landscape
8.3.1. List Of Key Distributors And Channel Partners
8.3.2. Key Customers
8.3.3. Key Company Market Share Analysis, 2023
8.3.4. CELONIC Group
8.3.4.1. Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Bio Elpida
8.3.5.1. Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Rentschler Biopharma SE
8.3.6.1. Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. AGC Biologics
8.3.7.1. Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Catalent, Inc.
8.3.8.1. Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Lonza
8.3.9.1. Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Wuxi Advanced Therapies
8.3.10.1. Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. Minaris Regenerative Medicine
8.3.11.1. Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. Patheon, Inc.
8.3.12.1. Overview
8.3.12.2. Financial Performance
8.3.12.3. Product Benchmarking
8.3.12.4. Strategic Initiatives
8.3.13. CGT Catapult
8.3.13.1. Overview
8.3.13.2. Financial Performance
8.3.13.3. Product Benchmarking
8.3.13.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018-2030 (USD Million)
Table 3 North America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 4 North America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 5 North America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 6 U.S. Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 7 U.S. Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 8 U.S. Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 9 Canada Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 10 Canada Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 11 Canada Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 12 Europe Advanced Therapy Medicinal Products CDMO Market, by Region, 2018-2030 (USD Million)
Table 13 Europe Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 14 Europe Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 15 Europe Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 16 UK Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 17 UK Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 18 UK Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 19 Germany Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 20 Germany Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 21 Germany Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 22 France Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 23 France Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 24 France Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 25 Italy Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 26 Italy Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 27 Italy Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 28 Spain Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 29 Spain Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 30 Spain Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 31 Sweden Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 32 Sweden Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 33 Sweden Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 34 Norway Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 35 Norway Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 36 Norway Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 37 Denmark Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 38 Denmark Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 39 Denmark Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 40 Asia-Pacific Advanced Therapy Medicinal Products CDMO Market, by Region, 2018-2030 (USD Million)
Table 41 Asia-Pacific Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 42 Asia-Pacific Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 43 Asia-Pacific Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 44 Japan Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 45 Japan Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 46 Japan Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 47 China Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 48 China Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 49 China Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 50 India Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 51 India Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 52 India Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 53 Australia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 54 Australia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 55 Australia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 56 South Korea Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 57 South Korea Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 58 South Korea Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 59 Thailand Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 60 Thailand Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 61 Thailand Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 62 Latin America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018-2030 (USD Million)
Table 63 Latin America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 64 Latin America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 65 Latin America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 66 Brazil Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 67 Brazil Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 68 Brazil Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 69 Argentina Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 70 Argentina Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 71 Argentina Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 72 Mexico Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 73 Mexico Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 74 Mexico Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 75 MEA Advanced Therapy Medicinal Products CDMO Market, by Region, 2018-2030 (USD Million)
Table 76 MEA Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 77 MEA Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 78 MEA Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 79 South Africa Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 80 South Africa Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 81 South Africa Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 82 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 83 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 84 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 85 UAE Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 86 UAE Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 87 UAE Advanced Therapy Medicinal Products CDMO Market, Indication, 2018-2030 (USD Million)
Table 88 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Product, 2018-2030 (USD Million)
Table 89 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018-2030 (USD Million)
Table 90 Kuwait Advanced Therapy Medicinal Products CDMO Market, Test type, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary Research Pattern
Fig. 4 Primary Interviews In North America
Fig. 5 Primary Interviews In Europe
Fig. 6 Primary Interviews In Asia-Pacific
Fig. 7 Primary Interviews In Latin America
Fig. 8 Primary Interviews In Middle East & Africa
Fig. 9 Market Research Approaches
Fig. 10 Value-Chain-Based Sizing & Forecasting
Fig. 11 QFD Modeling For Market Share Assessment
Fig. 12 Market Formulation & Validation
Fig. 13 Advanced Therapy Medicinal Products CDMO Market: Market Outlook
Fig. 14 Advanced Therapy Medicinal Products CDMO Competitive Insights
Fig. 15 Parent Market Outlook
Fig. 16 Related/Ancillary Market Outlook
Fig. 17 Penetration And Growth Prospect Mapping
Fig. 18 Industry Value Chain Analysis
Fig. 19 Advanced Therapy Medicinal Products CDMO Market Driver Impact
Fig. 20 Advanced Therapy Medicinal Products CDMO Market Restraint Impact
Fig. 21 Advanced Therapy Medicinal Products CDMO Market Strategic Initiatives Analysis
Fig. 22 Advanced Therapy Medicinal Products CDMO Market: Product Movement Analysis
Fig. 23 Advanced Therapy Medicinal Products CDMO Market: Product Outlook And Key Takeaways
Fig. 24 Gene Therapy Market Estimates And Forecast, 2018-2030
Fig. 25 Cell Therapy Estimates And Forecast, 2018-2030
Fig. 26 Tissue Engineered Estimates And Forecast, 2018-2030
Fig. 27 Others Estimates And Forecast, 2018-2030
Fig. 28 Advanced Therapy Medicinal Products CDMO Market: Phase Movement Analysis
Fig. 29 Advanced Therapy Medicinal Products CDMO Market: Phase Outlook And Key Takeaways
Fig. 30 Phase I Market Estimates And Forecasts, 2018-2030
Fig. 31 Phase II Market Estimates And Forecasts, 2018-2030
Fig. 32 Phase III Market Estimates And Forecasts, 2018-2030
Fig. 33 Phase IV Market Estimates And Forecasts, 2018-2030
Fig. 34 Advanced Therapy Medicinal Products CDMO Market: Indication Movement Analysis
Fig. 35 Advanced Therapy Medicinal Products CDMO Market: Indication Outlook And Key Takeaways
Fig. 36 Oncology Market Estimates And Forecasts, 2018-2030
Fig. 37 Cardiology Market Estimates And Forecasts,2018-2030
Fig. 38 Central Nervous System Estimates And Forecasts, 2018-2030
Fig. 39 Musculoskeletal Estimates And Forecasts, 2018-2030
Fig. 40 Infectious Disease Estimates And Forecasts, 2018-2030
Fig. 41 Dermatology Estimates And Forecasts, 2018-2030
Fig. 42 Others Estimates And Forecasts, 2018-2030
Fig. 43 Global Advanced Therapy Medicinal Products CDMO Market: Regional Movement Analysis
Fig. 44 Global Advanced Therapy Medicinal Products CDMO Market: Regional Outlook And Key Takeaways
Fig. 45 Global Advanced Therapy Medicinal Products CDMO Market Share And Leading Players
Fig. 46 North America Market Share And Leading Players
Fig. 47 Europe Market Share And Leading Players
Fig. 48 Asia-Pacific Market Share And Leading Players
Fig. 49 Latin America Market Share And Leading Players
Fig. 50 Middle East & Africa Market Share And Leading Players
Fig. 51 North America: SWOT
Fig. 52 Europe SWOT
Fig. 53 Asia-Pacific SWOT
Fig. 54 Latin America SWOT
Fig. 55 MEA SWOT
Fig. 56 North America
Fig. 57 North America Market Estimates And Forecasts, 2018-2030
Fig. 58 U.S.
Fig. 59 U.S. Market Estimates And Forecasts, 2018-2030
Fig. 60 Canada
Fig. 61 Canada Market Estimates And Forecasts, 2018-2030
Fig. 62 Europe
Fig. 63 Europe Market Estimates And Forecasts, 2018-2030
Fig. 64 UK
Fig. 65 UK Market Estimates And Forecasts, 2018-2030
Fig. 66 Germany
Fig. 67 Germany Market Estimates And Forecasts, 2018-2030
Fig. 68 France
Fig. 69 France Market Estimates And Forecasts, 2018-2030
Fig. 70 Italy
Fig. 71 Italy Market Estimates And Forecasts, 2018-2030
Fig. 72 Spain
Fig. 73 Spain Market Estimates And Forecasts, 2018-2030
Fig. 74 Denmark
Fig. 75 Denmark Market Estimates And Forecasts, 2018-2030
Fig. 76 Sweden
Fig. 77 Sweden Market Estimates And Forecasts, 2018-2030
Fig. 78 Norway
Fig. 79 Norway Market Estimates And Forecasts, 2018-2030
Fig. 80 Asia-Pacific
Fig. 81 Asia-Pacific Market Estimates And Forecasts, 2018-2030
Fig. 82 China
Fig. 83 China Market Estimates And Forecasts, 2018-2030
Fig. 84 Japan
Fig. 85 Japan Market Estimates And Forecasts, 2018-2030
Fig. 86 India
Fig. 87 India Market Estimates And Forecasts, 2018-2030
Fig. 88 Thailand
Fig. 89 Thailand Market Estimates And Forecasts, 2018-2030
Fig. 90 South Korea
Fig. 91 South Korea Market Estimates And Forecasts, 2018-2030
Fig. 92 Australia
Fig. 93 Australia Market Estimates And Forecasts, 2018-2030
Fig. 94 Latin America
Fig. 95 Latin America Market Estimates And Forecasts, 2018-2030
Fig. 96 Brazil
Fig. 97 Brazil Market Estimates And Forecasts, 2018-2030
Fig. 98 Mexico
Fig. 99 Mexico Market Estimates And Forecasts, 2018-2030
Fig. 100 Argentina
Fig. 101 Argentina Market Estimates And Forecasts, 2018-2030
Fig. 102 Middle East And Africa
Fig. 103 Middle East And Africa Market Estimates And Forecasts, 2018-2030
Fig. 104 South Africa
Fig. 105 South Africa Market Estimates And Forecasts, 2018-2030
Fig. 106 Saudi Arabia
Fig. 107 Saudi Arabia Market Estimates And Forecasts, 2018-2030
Fig. 108 UAE
Fig. 109 UAE Market Estimates And Forecasts, 2018-2030
Fig. 110 Kuwait
Fig. 111 Kuwait Market Estimates And Forecasts, 2018-2030
Fig. 112 Market Share Of Key Market Players - Advanced Therapy Medicinal Products CDMO Market

Companies Mentioned

  • CELONIC Group
  • Bio Elpida
  • Rentschler Biopharma SE
  • AGC Biologics
  • Catalent, Inc.
  • Lonza
  • Wuxi Advanced Therapies
  • Minaris Regenerative Medicine
  • Patheon, Inc.
  • CGT Catapult

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedJanuary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 5.64 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.8 Billion
Compound Annual Growth Rate18.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Advanced Therapy Medicinal Products CDMO Market by Products, Phase, Indication, End-Users - Global Forecast 2025-2030 - Product Image

Advanced Therapy Medicinal Products CDMO Market by Products, Phase, Indication, End-Users - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024 - Product Image

Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report by Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Product), Region (North America, Europe, APAC, ROW), and Segment Forecasts, 2023-2030 - Product Image

Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report by Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Product), Region (North America, Europe, APAC, ROW), and Segment Forecasts, 2023-2030

  • Report
  • 120 Pages
  • Global
From
Cell & Gene Therapy Biomanufacturing CDMO Market by Component, Phase, Indication - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Biomanufacturing CDMO Market by Component, Phase, Indication - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.